mesenchymal stem cell

Overview

Mesenchymal stem cells (MSCs), also called mesenchymal stromal cells or multipotent stromal cells, are a multipotent, plastic-adherent cell type resident in the stromal compartment of many tissues — most prominently bone marrow, umbilical cord, adipose tissue, and the dental pulp of exfoliated deciduous teeth (the source of SHED). They act as progenitor and support cells rather than terminally differentiated cells: they can differentiate along osteogenic, chondrogenic, and adipogenic lineages, and under defined stimulation can be directed toward other fates, including insulin-producing cells. In their native niche, MSCs help build the microenvironment that sustains neighboring populations; in bone marrow they contribute to the stromal network supporting hematopoietic stem cell retention and maintenance. Preparations are frequently named by tissue of origin — bone marrow–derived (BMSC), umbilical cord–derived (UC-MSC), and SHED — and clinical material is often obtained from concentrated bone marrow aspirate.

The therapeutic interest in MSCs rests less on direct structural replacement of damaged tissue than on their immunomodulatory and trophic activity. MSCs secrete a broad range of bioactive factors and release extracellular vesicles, including exosomes carrying microRNAs and proteins, that act on surrounding cells in a paracrine fashion — dampening proinflammatory cytokine signaling such as TNF-α, limiting oxidative stress and Intracellular ROS, and engaging survival and growth signaling through the PTEN/PI3K/Akt/mTOR axis. This repertoire underlies the range of conditions in which MSC transplantation has been explored: inflammatory and immune-mediated disease, chronic renal insufficiency, diabetes, myocardial infarction, spinal cord and other neurological injury, neonatal lung injury and bronchopulmonary dysplasia, post-infectious hydrocephalus, and hepatic fibrosis. A recurring limitation is that transplanted MSCs survive poorly and lose stable secretory function in hostile microenvironments such as the infarcted heart, and the cells are themselves prone to cellular senescence with expansion and donor age. Much current work therefore targets the delivery context — hydrogels and microgels of tuned stiffness, decellularized extracellular matrix, chitosan and other biomaterial carriers, aptamer-based enrichment of endogenous cells, and priming agents such as platelet-rich plasma or melatonin — to enrich, retain, and sustain MSC function at the injury site, or on using MSC-derived extracellular vesicles as a cell-free alternative.

Recent Publications Summary

Recent publications on mesenchymal stem cells (MSCs) focused heavily on regenerative and immunomodulatory applications across bone, lung, kidney, liver, nervous system, and inflammatory disease models. In bone tissue engineering, an aptamer-functionalized stiffness-gradient hydrogel was designed to enrich endogenous bone marrow-derived mesenchymal stem cells (BMSCs) and simultaneously direct osteogenesis; the combined “enrich-and-differentiate” strategy produced higher alkaline phosphatase activity, increased RUNX2/osteocalcin expression, and greater mineralization than either cue alone 42461853Jul. Related biomaterial studies also used MSCs as a central component of engineered niches, including a microgel bone marrow model supporting MSC paracrine signaling for hematopoietic stem cell retention 42248284Jun and an ECM-inspired supramolecular cryogel for 3D culture of mini-bone trabeculae tissue analogs 42068993May. In diabetic bone repair, a ROS-responsive composite hydrogel was designed to modulate the immune-osteogenic cascade and restore BMSC mitochondrial homeostasis 42101831May, while melatonin was investigated for improving osteogenic differentiation under high-glucose conditions through NRF2-mediated autophagy and macrophage-BMSC cross-talk 42096091May.

Several studies examined MSC-based strategies for pulmonary and neurologic injury. A phase II multicentre randomized trial protocol (HULC-2) is evaluating repeated intravenous umbilical cord-derived MSCs in extremely preterm infants at risk of bronchopulmonary dysplasia 42409407Jul, and a separate phase II randomized clinical trial assessed Wharton’s Jelly-derived MSCs for respiratory complications of COVID-19 42134096May. In the nervous system, a first-in-human case report described intraventricular administration of SHED-derived MSCs in neonatal post-infectious hydrocephalus, reporting technical feasibility, short-term procedural safety, and concurrent clinical and imaging improvements, while emphasizing the major confounding effect of cerebrospinal fluid diversion 42362959Jun. MSCs were also explored in progressive multiple sclerosis in a randomized, double-blind, placebo-controlled intrathecal trial 42081777May, and in chronic stroke, where human umbilical cord-derived MSC transplantation combined with intermittent theta-burst stimulation was associated with robust neurogenesis in a monkey model 42031725Apr. In spinal cord injury, platelet-rich plasma-primed BMSC-derived exosomes were reported to inhibit neuronal apoptosis and autophagy and promote nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis 42165939May.

Other publications highlighted MSCs as systemic anti-inflammatory or organ-protective therapies. A case report in juvenile-onset rheumatoid arthritis with dialysis-dependent renal failure described reduced inflammatory markers, improved hemoglobin, and favorable renal trends after three systemic MSC administrations 42286909Jun. In diabetic kidney disease, both MSCs and MSC-conditioned media attenuated glomerular injury, preserved podocyte integrity, reduced NOX4 expression, and inhibited mTORC1/mTORC2 signaling, with conditioned media reproducing the renoprotective effects of cells 41811297Mar. Hypoxia-preconditioned BMSCs were investigated for acute liver failure, with the study focusing on VEGF-related factors and B-cell immunity 42165955May, and a real-world evidence study assessed autologous bone marrow-derived MSC transplantation for decompensated liver cirrhosis 40916722Sep. MSC-derived exosomes were also tested in a murine aspiration model for lung inflammation 41699868Feb, and MSC transplantation was examined in nonalcoholic fatty liver disease associated with polycystic ovary syndrome 42057606Apr. In addition, a study in aged macaques used 18F-FDG PET/CT imaging to evaluate the anti-aging effects of BMMSCs in the brain 42145043May.

Across these reports, MSCs were frequently paired with biomaterials, preconditioning approaches, secretome/exosome preparations, or adjunctive physical and pharmacologic interventions to improve efficacy. Examples include bioprinted dECM particle-laden microgels that enhanced MSC paracrine function and improved cardiac outcomes after myocardial infarction 42250666Jun, and a straw-reinforced-clay-inspired composite hydrogel intended to support diabetic bone regeneration by reshaping the immune-osteogenic environment 42101831May. In the kidney and liver literature, MSCs were studied as cell therapies or as sources of conditioned media, with emphasis on inflammation, oxidative stress, and pathway modulation 41811297Mar42165955May40916722Sep. Collectively, these publications portray MSCs as a versatile target in translational research, with ongoing efforts to improve cell sourcing, survival, paracrine activity, and tissue-specific delivery while extending applications from preclinical models into early clinical studies 42409407Jul42081777May42362959Jun.

What Changes, What Holds

1. MSCs are being used as active niche-building and osteoinductive tools, not just generic progenitors
REINFORCES Aptamer-guided enrichment and stiffness tuning sharpen the baseline view that MSCs can be recruited, retained, and directed by their microenvironment, especially in bone repair 42461853Jul. The added biomaterial and 3D niche studies do not overturn the established account; they strengthen it by showing that delivery context and local mechanics can materially amplify osteogenesis and paracrine support, while also underscoring that much of the field now depends on engineered scaffolds rather than cells alone 42248284Jun42068993May.

2. Clinical translation is moving from broad promise to specific, still-unsettled indications
REINFORCES Repeated intravenous or intrathecal MSC use in preterm lung disease, COVID-19 respiratory complications, progressive multiple sclerosis, and neonatal hydrocephalus fits the baseline’s claim that MSCs are being explored for inflammatory and neurological injury, but it does not yet establish durable efficacy 42409407Jul42134096May42081777May42362959Jun. The new work mainly shows that the therapeutic agenda is expanding into early clinical testing, while the hydrocephalus report also highlights how hard it is to separate cell effects from concurrent procedures.

3. MSCs continue to look more like systemic immunomodulators and organ protectors than simple replacement cells
REINFORCES The kidney, liver, and arthritis reports extend the baseline’s emphasis on paracrine and anti-inflammatory activity, with conditioned media reproducing some cell effects and pathway changes tracking reduced injury 42286909Jun41811297Mar42165955May40916722Sep. Nothing here displaces the established mechanism; instead, these studies reinforce that the main therapeutic signal is still trophic and immunologic, while also suggesting that secreted products may sometimes capture much of the benefit without live-cell transplantation.

4. Delivery engineering and adjunctive priming remain the main route to making MSC therapy work
REINFORCES Bioprinted matrices, composite hydrogels, preconditioning, and exosome priming all align with the baseline’s concern that transplanted MSCs survive poorly and need help to function in hostile tissue 42250666Jun42101831May42165939May. The new publications do not change the core model; they sharpen it by showing that efficacy is increasingly being sought through niche design, secretome enhancement, and combination strategies rather than through unmodified cell infusion alone.

Overview update candidates: engineered niches and biomaterial-assisted delivery as a central translational strategy; early clinical testing in lung; neurologic; and inflammatory disease; conditioned media/exosome approaches as partial cell-free substitutes.